Tvardi Therapeutics Inc
Company Profile
Business description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USAT: +1 713 489-8654
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,106.50 | 47.00 | 0.52% |
| CAC 40 | 8,437.89 | 74.75 | 0.89% |
| DAX 40 | 25,155.41 | 144.06 | 0.58% |
| Dow JONES (US) | 52,218.58 | 6.06 | -0.01% |
| FTSE 100 | 10,716.97 | 131.06 | 1.24% |
| HKSE | 24,966.53 | 73.87 | 0.30% |
| NASDAQ | 25,690.90 | 146.30 | -0.57% |
| Nikkei 225 | 66,783.17 | 667.57 | 1.01% |
| NZX 50 Index | 13,796.20 | 33.02 | 0.24% |
| S&P 500 | 7,498.96 | 10.24 | -0.14% |
| S&P/ASX 200 | 8,924.60 | 47.00 | 0.53% |
| SSE Composite Index | 3,866.66 | 0.38 | -0.01% |